Shots:
- Alector to receive $700M as up front and is eligible to receive ~$1.5B as milestones. The companies collaborated to co-develop AL001 and AL101 for frontotemporal dementia, ALS, PD and AD
- Alector will lead the development of the therapies through P-II POC while the companies will share development costs for therapies. The companies will co-commercialize therapies and share profits/losses in the US while GSK will retain exclusive commercialization rights outside the US, for which Alector will be eligible for royalties
- Alector will lead commercial efforts associated with AL001 in orphan indications and GSK will lead the commercialization of AL101 in AD & PD
Click here to read full press release/ article | Ref: GSK | Image: Bloomberg Quint
The post GSK and Alector Sign $2.2B Collaboration to Develop Therapies for Neurodegenerative Diseases first appeared on PharmaShots.
